NCT00973011View on ClinicalTrials.gov

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy

PHASE1CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions

Geographic Atrophy

Interventions

DRUG

FCFD4514S

Intravitreal escalating dose

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY

NCT00973011 - A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy | Biotech Hunter | Biotech Hunter